Please login to the form below

Not currently logged in
Email:
Password:

Efficacy trials get underway for HIV vaccine in South Africa

Study hopes to provide partial immunity against the virus

Amazing Africa 

Researchers are testing an HIV vaccine in efficacy trials for the first time in seven years in the hope that the candidate will provide at least partial immunity against the virus.

The study - called HVTN 702 - is being conducted in South Africa and will test an updated version of an experimental vaccine developed by researchers at the US National Institute of Allergy and Infectious Diseases (NIAID) that was shown to have around 32% efficacy in an earlier trial (RV144).

The vaccine regimen is based on a canarypox vector-based vaccine called ALVAC-HIV from Sanofi Pasteur and a two-component gp120 protein subunit vaccine supplied by GlaxoSmithKline (GSK), and should yield results in 2020.

The new regimen has been altered to try to increase the magnitude and duration of immune responses to the vaccine, for example by targeting a subtype of HIV predominant in South Africa, increasing the number of shots and incorporating an immune-stimulating adjuvant (MF59) also supplied by GSK.

Around 5,400 men and women will be enrolled in HVTN 702 and will receive an initial vaccination with the regimen followed by a booster shot a year later. The safety of the vaccine was shown in a smaller study (HVTN 100).

NIAID director Anthony Fauci said that even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection such as South Africa, which sees more than 1,000 people newly infected with the virus every day.

"If deployed alongside our current armoury of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," he predicted.

The HIV Vaccine Trials Network - part of the P5 public-private partnership behind the vaccine's development along with the organiser of the trial - has said that it believes that if the vaccine can show a 50% protective efficacy rate at two years it could be enough to support regulatory approvals.

In addition to the NIAID, the two pharma companies and the HVTN, the P5 brings together the Bill & Melinda Gates Foundation (BMGF), the South African Medical Research Council and the US Military HIV Research Programme.

HVTN 702 is being funded to the tune of $130m, with the bulk of that money coming from the NIAID and BMGF.

Article by
Phil Taylor

29th November 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics